de Godoy, Laiz Laura
Chawla, Sanjeev
Brem, Steven
Wang, Sumei
O’Rourke, Donald M.
Nasrallah, MacLean P.
Desai, Arati
Loevner, Laurie A.
Liau, Linda M.
Mohan, Suyash
Article History
Received: 15 February 2023
Accepted: 24 April 2023
First Online: 2 May 2023
Declarations
:
: Dr. S. Brem received partial support of travel expenses in 2022 from Northwest Biotherapeutics. The remaining authors do not have any potential conflicts of interest.
: This study was performed in line with the principles of the Declaration of Helsinki. The DCVax-L trial at the University of Pennsylvania, “A Phase-3 Clinical Trial Evaluating DC Vax®L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme” was sponsored by Northwest Biotherapeutics, using the protocol, NCT00045968. It was approved by the Abramson Cancer Center—CTSRMC (Clinical Trials Scientific Review Committee (UPCC # 34313) and the Institutional Review Board (#81817).
: Informed consent was obtained from all individual participants included in the study.